The effect of conjugated equine oestrogen on diabetes incidence: The Women's Health Initiative randomised trial

D. E. Bonds, N. Lasser, L. Qi, R. Brzyski, B. Caan, G. Heiss, M. C. Limacher, J. H. Liu, E. Mason, A. Oberman, M. J. O'Sullivan, L. S. Phillips, R. J. Prineas, L. Tinker

Research output: Contribution to journalArticle

140 Citations (Scopus)

Abstract

Aims/hypothesis: Recent clinical trials have found that the combination of conjugated equine oestrogen (CEO) and medroxyprogesterone has a protective effect on the incidence of type 2 diabetes. To determine the effect of CEO alone on the incidence of diabetes mellitus in postmenopausal women, we analysed the results of the Women's Health Initiative oestrogen-alone trial. Methods: The Women's Health Initiative is a randomised, double-masked trial comparing the effect of daily 0.625 mg CEO with placebo during 7.1 years of follow-up of 10,739 postmenopausal women who were aged 50-79 years and had previously had a hysterectomy. Diabetes incidence was ascertained by self-report of treatment with insulin or oral hypoglycaemic medication. Fasting glucose, insulin and lipoproteins were measured in an 8.6% random sample of study participants, at baseline and at 1, 3 and 6 years. Results: The cumulative incidence of treated diabetes was 8.3% in the oestrogen-alone group and 9.3% in the placebo group (hazard ratio 0.88, 95% CI 0.77-1.01, p=0.072). During the first year of follow-up, a significant fall in insulin resistance (homeostasis model assessment of insulin resistance) in actively treated women compared with the control subjects (Year 1 baseline between-group difference -0.53) was seen. However, there was no difference in insulin resistance at the 3- or 6-year follow-up. Conclusions/interpretation: Postmenopausal therapy with oestrogen alone may reduce the incidence of treated diabetes. The effect is smaller than that seen with oestrogen plus progestin. CEO should not, however, be used with the intention of preventing diabetes, as its well-described adverse effects preclude long-term use for primary prevention.

Original languageEnglish
Pages (from-to)459-468
Number of pages10
JournalDiabetologia
Volume49
Issue number3
DOIs
StatePublished - Mar 1 2006
Externally publishedYes

Fingerprint

Conjugated (USP) Estrogens
Women's Health
Estrogens
Incidence
Insulin Resistance
Medroxyprogesterone
Placebos
Insulin
Progestins
Primary Prevention
Hysterectomy
Hypoglycemic Agents
Self Report
Type 2 Diabetes Mellitus
Lipoproteins
Fasting
Diabetes Mellitus
Homeostasis
Clinical Trials
Glucose

Keywords

  • Conjugated equine oestrogen
  • Diabetes mellitus
  • Postmenopausal
  • Randomised double-masked trial

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Bonds, D. E., Lasser, N., Qi, L., Brzyski, R., Caan, B., Heiss, G., ... Tinker, L. (2006). The effect of conjugated equine oestrogen on diabetes incidence: The Women's Health Initiative randomised trial. Diabetologia, 49(3), 459-468. https://doi.org/10.1007/s00125-005-0096-0

The effect of conjugated equine oestrogen on diabetes incidence : The Women's Health Initiative randomised trial. / Bonds, D. E.; Lasser, N.; Qi, L.; Brzyski, R.; Caan, B.; Heiss, G.; Limacher, M. C.; Liu, J. H.; Mason, E.; Oberman, A.; O'Sullivan, M. J.; Phillips, L. S.; Prineas, R. J.; Tinker, L.

In: Diabetologia, Vol. 49, No. 3, 01.03.2006, p. 459-468.

Research output: Contribution to journalArticle

Bonds, DE, Lasser, N, Qi, L, Brzyski, R, Caan, B, Heiss, G, Limacher, MC, Liu, JH, Mason, E, Oberman, A, O'Sullivan, MJ, Phillips, LS, Prineas, RJ & Tinker, L 2006, 'The effect of conjugated equine oestrogen on diabetes incidence: The Women's Health Initiative randomised trial', Diabetologia, vol. 49, no. 3, pp. 459-468. https://doi.org/10.1007/s00125-005-0096-0
Bonds, D. E. ; Lasser, N. ; Qi, L. ; Brzyski, R. ; Caan, B. ; Heiss, G. ; Limacher, M. C. ; Liu, J. H. ; Mason, E. ; Oberman, A. ; O'Sullivan, M. J. ; Phillips, L. S. ; Prineas, R. J. ; Tinker, L. / The effect of conjugated equine oestrogen on diabetes incidence : The Women's Health Initiative randomised trial. In: Diabetologia. 2006 ; Vol. 49, No. 3. pp. 459-468.
@article{3de2e4b042134a6ea24d2565352c834d,
title = "The effect of conjugated equine oestrogen on diabetes incidence: The Women's Health Initiative randomised trial",
abstract = "Aims/hypothesis: Recent clinical trials have found that the combination of conjugated equine oestrogen (CEO) and medroxyprogesterone has a protective effect on the incidence of type 2 diabetes. To determine the effect of CEO alone on the incidence of diabetes mellitus in postmenopausal women, we analysed the results of the Women's Health Initiative oestrogen-alone trial. Methods: The Women's Health Initiative is a randomised, double-masked trial comparing the effect of daily 0.625 mg CEO with placebo during 7.1 years of follow-up of 10,739 postmenopausal women who were aged 50-79 years and had previously had a hysterectomy. Diabetes incidence was ascertained by self-report of treatment with insulin or oral hypoglycaemic medication. Fasting glucose, insulin and lipoproteins were measured in an 8.6{\%} random sample of study participants, at baseline and at 1, 3 and 6 years. Results: The cumulative incidence of treated diabetes was 8.3{\%} in the oestrogen-alone group and 9.3{\%} in the placebo group (hazard ratio 0.88, 95{\%} CI 0.77-1.01, p=0.072). During the first year of follow-up, a significant fall in insulin resistance (homeostasis model assessment of insulin resistance) in actively treated women compared with the control subjects (Year 1 baseline between-group difference -0.53) was seen. However, there was no difference in insulin resistance at the 3- or 6-year follow-up. Conclusions/interpretation: Postmenopausal therapy with oestrogen alone may reduce the incidence of treated diabetes. The effect is smaller than that seen with oestrogen plus progestin. CEO should not, however, be used with the intention of preventing diabetes, as its well-described adverse effects preclude long-term use for primary prevention.",
keywords = "Conjugated equine oestrogen, Diabetes mellitus, Postmenopausal, Randomised double-masked trial",
author = "Bonds, {D. E.} and N. Lasser and L. Qi and R. Brzyski and B. Caan and G. Heiss and Limacher, {M. C.} and Liu, {J. H.} and E. Mason and A. Oberman and O'Sullivan, {M. J.} and Phillips, {L. S.} and Prineas, {R. J.} and L. Tinker",
year = "2006",
month = "3",
day = "1",
doi = "10.1007/s00125-005-0096-0",
language = "English",
volume = "49",
pages = "459--468",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - The effect of conjugated equine oestrogen on diabetes incidence

T2 - The Women's Health Initiative randomised trial

AU - Bonds, D. E.

AU - Lasser, N.

AU - Qi, L.

AU - Brzyski, R.

AU - Caan, B.

AU - Heiss, G.

AU - Limacher, M. C.

AU - Liu, J. H.

AU - Mason, E.

AU - Oberman, A.

AU - O'Sullivan, M. J.

AU - Phillips, L. S.

AU - Prineas, R. J.

AU - Tinker, L.

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Aims/hypothesis: Recent clinical trials have found that the combination of conjugated equine oestrogen (CEO) and medroxyprogesterone has a protective effect on the incidence of type 2 diabetes. To determine the effect of CEO alone on the incidence of diabetes mellitus in postmenopausal women, we analysed the results of the Women's Health Initiative oestrogen-alone trial. Methods: The Women's Health Initiative is a randomised, double-masked trial comparing the effect of daily 0.625 mg CEO with placebo during 7.1 years of follow-up of 10,739 postmenopausal women who were aged 50-79 years and had previously had a hysterectomy. Diabetes incidence was ascertained by self-report of treatment with insulin or oral hypoglycaemic medication. Fasting glucose, insulin and lipoproteins were measured in an 8.6% random sample of study participants, at baseline and at 1, 3 and 6 years. Results: The cumulative incidence of treated diabetes was 8.3% in the oestrogen-alone group and 9.3% in the placebo group (hazard ratio 0.88, 95% CI 0.77-1.01, p=0.072). During the first year of follow-up, a significant fall in insulin resistance (homeostasis model assessment of insulin resistance) in actively treated women compared with the control subjects (Year 1 baseline between-group difference -0.53) was seen. However, there was no difference in insulin resistance at the 3- or 6-year follow-up. Conclusions/interpretation: Postmenopausal therapy with oestrogen alone may reduce the incidence of treated diabetes. The effect is smaller than that seen with oestrogen plus progestin. CEO should not, however, be used with the intention of preventing diabetes, as its well-described adverse effects preclude long-term use for primary prevention.

AB - Aims/hypothesis: Recent clinical trials have found that the combination of conjugated equine oestrogen (CEO) and medroxyprogesterone has a protective effect on the incidence of type 2 diabetes. To determine the effect of CEO alone on the incidence of diabetes mellitus in postmenopausal women, we analysed the results of the Women's Health Initiative oestrogen-alone trial. Methods: The Women's Health Initiative is a randomised, double-masked trial comparing the effect of daily 0.625 mg CEO with placebo during 7.1 years of follow-up of 10,739 postmenopausal women who were aged 50-79 years and had previously had a hysterectomy. Diabetes incidence was ascertained by self-report of treatment with insulin or oral hypoglycaemic medication. Fasting glucose, insulin and lipoproteins were measured in an 8.6% random sample of study participants, at baseline and at 1, 3 and 6 years. Results: The cumulative incidence of treated diabetes was 8.3% in the oestrogen-alone group and 9.3% in the placebo group (hazard ratio 0.88, 95% CI 0.77-1.01, p=0.072). During the first year of follow-up, a significant fall in insulin resistance (homeostasis model assessment of insulin resistance) in actively treated women compared with the control subjects (Year 1 baseline between-group difference -0.53) was seen. However, there was no difference in insulin resistance at the 3- or 6-year follow-up. Conclusions/interpretation: Postmenopausal therapy with oestrogen alone may reduce the incidence of treated diabetes. The effect is smaller than that seen with oestrogen plus progestin. CEO should not, however, be used with the intention of preventing diabetes, as its well-described adverse effects preclude long-term use for primary prevention.

KW - Conjugated equine oestrogen

KW - Diabetes mellitus

KW - Postmenopausal

KW - Randomised double-masked trial

UR - http://www.scopus.com/inward/record.url?scp=33244469258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33244469258&partnerID=8YFLogxK

U2 - 10.1007/s00125-005-0096-0

DO - 10.1007/s00125-005-0096-0

M3 - Article

C2 - 16440209

AN - SCOPUS:33244469258

VL - 49

SP - 459

EP - 468

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 3

ER -